What Is Mounjaro? Tirzepatide for Weight Loss Explained
Start Your Mounjaro Journey
Complete a free online consultation reviewed by GPhC-registered pharmacist independent prescribers. Mounjaro delivered to your door — usually next day.
View Weight Loss Treatments →What Is Mounjaro?
Mounjaro is the brand name for tirzepatide — a once-weekly injectable prescription medication and the most effective weight loss injection currently available in the UK. It is manufactured by Eli Lilly and received MHRA approval for chronic weight management in November 2023, following its earlier approval for type 2 diabetes management.
Tirzepatide belongs to a new class of medication: a dual GIP and GLP-1 receptor agonist. Unlike previous generation weight loss injections that act on one hormone pathway, Mounjaro simultaneously activates two gut-derived hormone receptors — producing a more powerful and sustained reduction in appetite, calorie intake, and body weight.
Clinical trials have demonstrated weight loss results that were previously achievable only through bariatric surgery — making Mounjaro a genuinely transformative development in obesity medicine.
MHRA approved: Mounjaro (tirzepatide) received MHRA approval in the UK for chronic weight management in adults with obesity or overweight with comorbidities. It is a prescription-only medicine — a medical consultation is required before it can be dispensed.
How Mounjaro Works
To understand why Mounjaro is so effective, it helps to understand the two hormone pathways it activates:
GLP-1 (Glucagon-Like Peptide-1)
Released after eating, GLP-1 signals fullness to the brain, slows gastric emptying, and stimulates insulin secretion. Activating this receptor reduces appetite and calorie intake — the same mechanism as liraglutide (Saxenda).
GIP (Glucose-Dependent Insulinotropic Polypeptide)
Also released after eating, GIP enhances insulin response and — uniquely — appears to amplify the appetite-suppressing effects of GLP-1 when both receptors are activated simultaneously. This dual action is what makes tirzepatide more effective than GLP-1 agonists alone.
Together, these two mechanisms reduce appetite more powerfully than either pathway alone, while also improving insulin sensitivity, reducing blood sugar, and favourably altering fat metabolism. Read our detailed explainer: How does Mounjaro work? The science behind tirzepatide.
Clinical Evidence: The SURMOUNT Trials
Mounjaro’s effectiveness for weight loss is supported by the SURMOUNT clinical trial programme — one of the largest and most rigorous obesity treatment trial series ever conducted.
- SURMOUNT-1: 2,539 adults with obesity (no diabetes). Mounjaro 15mg: 20.9% mean weight loss over 72 weeks. 91% lost ≥5%, 57% lost ≥20% of body weight.
- SURMOUNT-2: Adults with obesity and type 2 diabetes. Mounjaro 15mg: 15.7% mean weight loss — greater than any previous diabetes-obesity treatment.
- SURMOUNT-3: Mounjaro following intensive lifestyle intervention — 18.4% additional weight loss after initial lifestyle phase.
- SURMOUNT-4: Long-term maintenance study — continued treatment maintained weight loss; stopping led to weight regain, confirming ongoing treatment is needed.
For context, the previous gold-standard injectable — liraglutide (Saxenda) — produced an average 8% weight loss. Mounjaro more than doubles this outcome. See our full comparison: Mounjaro vs Saxenda: which is right for you?
Who Is Mounjaro Suitable For?
| Eligibility criterion | Detail |
|---|---|
| BMI ≥ 30 | Primary eligibility criterion (obesity) |
| BMI 27–29.9 + comorbidity | At least one weight-related condition: type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease |
| Age | Adults aged 18 and over |
| Lifestyle commitment | Must be used alongside reduced-calorie diet and increased physical activity |
Mounjaro is not suitable if you are pregnant or breastfeeding, have a personal or family history of medullary thyroid carcinoma or MEN2, have active pancreatitis, or are already taking another GLP-1 or GIP agonist. Full contraindications are assessed during your medical consultation.
Important: Mounjaro must be used alongside a calorie-reduced diet and increased physical activity — it is not a standalone treatment. The clinical trials demonstrating its results all required participants to maintain lifestyle changes throughout treatment.
Dosage & Administration
Mounjaro uses a gradual dose escalation protocol to minimise side effects — particularly gastrointestinal discomfort during the adjustment phase:
| Weeks | Weekly dose | Purpose |
|---|---|---|
| Weeks 1–4 | 2.5mg | Initiation — minimise GI side effects |
| Weeks 5–8 | 5mg | First maintenance option |
| Weeks 9–12 | 7.5mg | Escalation if tolerated |
| Weeks 13–16 | 10mg | Escalation if tolerated |
| Weeks 17–20 | 12.5mg | Escalation if tolerated |
| Week 21+ | 15mg | Maximum dose (optimal efficacy) |
Mounjaro is injected subcutaneously (under the skin) into the abdomen, upper thigh, or upper arm, using the pre-filled autoinjector pen. Inject on the same day each week. Injection sites should be rotated. Pens should be stored in the refrigerator (2–8°C) before first use.
Mounjaro vs Other Weight Loss Injections
| Feature | Mounjaro (tirzepatide) | Wegovy (semaglutide) | Saxenda (liraglutide) |
|---|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist | GLP-1 agonist |
| Frequency | Once weekly | Once weekly | Once daily |
| Avg. weight loss | ~20.9% body weight | ~15% body weight | ~8% body weight |
| MHRA approved (UK) | Yes — 2023 | Yes — 2023 | Yes — 2017 |
| Max dose | 15mg weekly | 2.4mg weekly | 3mg daily |
Getting Mounjaro in the UK
Mounjaro is a prescription-only medicine. It cannot be purchased over the counter. Access Doctor is a GPhC-registered online pharmacy. Complete a short online medical consultation reviewed by our GPhC-registered pharmacist independent prescribers. If your consultation is approved, Mounjaro is dispensed and dispatched in temperature-controlled, discreet packaging — typically arriving next working day via Royal Mail Tracked 24.
💉 Prescription Weight Loss
Mounjaro (Tirzepatide)
MHRA-approved once-weekly injection. Dual GIP & GLP-1 action — the most effective injectable weight loss treatment currently available in the UK.
View weight loss treatments →Ready to Start with Mounjaro?
Complete a free online consultation reviewed by GPhC-registered pharmacist independent prescribers. Discreet, temperature-controlled next-day delivery.
View Weight Loss Treatments →Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Mounjaro (tirzepatide) is a prescription-only medicine in the UK — always complete a full medical consultation before starting treatment. Always consult a qualified healthcare professional regarding your individual circumstances. In a medical emergency, call 999.
Frequently Asked Questions About Mounjaro
What is Mounjaro?
Mounjaro is the brand name for tirzepatide — a once-weekly injectable prescription medication approved by the MHRA for chronic weight management. It is a dual GIP and GLP-1 receptor agonist, activating two appetite-regulating pathways simultaneously — making it the most effective injectable weight loss treatment currently available in the UK.
How much weight can you lose with Mounjaro?
In the SURMOUNT-1 trial, adults using Mounjaro 15mg lost an average of 20.9% of body weight over 72 weeks — approximately 22kg in a 105kg adult. 91% of participants lost at least 5% and 57% lost at least 20% of their starting weight.
Who is eligible for Mounjaro in the UK?
Mounjaro is licensed for adults with a BMI of 30 or above, or BMI 27 or above with at least one weight-related health condition such as type 2 diabetes, hypertension, or dyslipidaemia. Eligibility is confirmed during a medical consultation with a GPhC-registered prescriber.
How is Mounjaro taken?
Mounjaro is injected subcutaneously once weekly via a pre-filled autoinjector pen. Treatment starts at 2.5mg weekly, increasing every four weeks up to a maximum of 15mg weekly depending on response and tolerability.
Is Mounjaro better than Saxenda?
Clinical evidence shows Mounjaro produces significantly greater weight loss than Saxenda (liraglutide) — approximately 20.9% vs 8% average body weight reduction. Mounjaro’s dual GIP and GLP-1 mechanism is more effective than GLP-1 action alone. See our full comparison: Mounjaro vs Saxenda.
Can I get Mounjaro online in the UK?
Yes — Access Doctor is a GPhC-registered online pharmacy. Complete a short online medical consultation reviewed by GPhC-registered pharmacist independent prescribers. If eligible, Mounjaro is dispatched for next-day delivery in temperature-controlled, discreet packaging.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022;387:205–216. Available at: nejm.org
- NICE. Tirzepatide for managing overweight and obesity (TA1026). National Institute for Health and Care Excellence. Available at: nice.org.uk/guidance/ta1026
- NHS. Obesity — Treatment. Available at: nhs.uk/conditions/obesity/treatment
- Electronic Medicines Compendium. Mounjaro solution for injection — SmPC. Available at: medicines.org.uk/emc
- NICE. Obesity: identification, assessment and management (CG189). Available at: nice.org.uk/guidance/cg189